ECSP024365A - Moleculas mutantes solubles ctla4 y sus aplicaciones - Google Patents

Moleculas mutantes solubles ctla4 y sus aplicaciones

Info

Publication number
ECSP024365A
ECSP024365A EC2002004365A ECSP024365A ECSP024365A EC SP024365 A ECSP024365 A EC SP024365A EC 2002004365 A EC2002004365 A EC 2002004365A EC SP024365 A ECSP024365 A EC SP024365A EC SP024365 A ECSP024365 A EC SP024365A
Authority
EC
Ecuador
Prior art keywords
ctla4
mutant molecules
applications
amino acid
molecules
Prior art date
Application number
EC2002004365A
Other languages
English (en)
Inventor
Juergen Bajorath
Robert J Peach
Joseph R Naemura
Peter S Linsley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP024365A publication Critical patent/ECSP024365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ofrece las moléculas mutantes CTLA4 solubles que se ligan con mayor intensidad a los antígenos CD80 y/o CD86 que a los CTLA4 de tipo agresivo o CTLA4 Ig no mutados. Las moléculas CTLA4 solubles tienen una primera secuencia de aminoácido conteniendo el dominio extracelular de CTLA4, donde ciertos residuos de aminoácidos son mutados en las regiones 825- R33 Y M97-G107. Las molécular mutantes de la invención pueden también incluir una segunda secuencia de aminoácidos que aumentan la solubilidad de las moléculas mutantes.
EC2002004365A 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones ECSP024365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
ECSP024365A true ECSP024365A (es) 2003-03-31

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004365A ECSP024365A (es) 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones

Country Status (41)

Country Link
EP (3) EP3029062A1 (es)
JP (1) JP4328525B2 (es)
KR (2) KR100889887B1 (es)
CN (2) CN101255192A (es)
AR (1) AR031699A1 (es)
AT (1) ATE271066T1 (es)
AU (2) AU6346601A (es)
BE (1) BE2011C041I2 (es)
BR (1) BRPI0111191B8 (es)
CA (1) CA2409748C (es)
CY (2) CY2011019I1 (es)
CZ (1) CZ304451B6 (es)
DE (2) DE60104282T2 (es)
DK (1) DK1248802T3 (es)
EC (1) ECSP024365A (es)
EE (2) EE05458B1 (es)
EG (1) EG24459A (es)
ES (2) ES2225549T3 (es)
FR (1) FR11C0053I2 (es)
GE (1) GEP20053658B (es)
HK (1) HK1048126B (es)
HU (2) HU228137B1 (es)
IL (1) IL152315A (es)
LT (1) LT5133B (es)
LU (1) LU91902I2 (es)
LV (1) LV12994B (es)
MX (1) MXPA02011534A (es)
MY (1) MY136113A (es)
NO (2) NO330797B1 (es)
PE (1) PE20011338A1 (es)
PL (1) PL206267B1 (es)
PT (1) PT1248802E (es)
RU (1) RU2283847C2 (es)
SI (1) SI1248802T1 (es)
SK (1) SK288131B6 (es)
TR (1) TR200402703T4 (es)
TW (2) TWI314933B (es)
UA (1) UA87432C2 (es)
UY (1) UY26723A1 (es)
WO (1) WO2001092337A2 (es)
ZA (1) ZA200208944B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU7317401A (en) * 2000-07-03 2002-01-14 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
PT1576182E (pt) 2002-12-23 2011-01-21 Bristol Myers Squibb Co Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2253644B1 (en) * 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
RU2506275C2 (ru) * 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
PL2344540T3 (pl) * 2008-10-02 2018-05-30 Aptevo Research And Development Llc Białka wiążące wiele celów antagonistyczne względem cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
AU2012220861A1 (en) 2011-02-23 2013-09-05 Amgen Inc. Cell culture media for UVC exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
SG11201405968SA (en) * 2012-05-11 2014-11-27 Medimmune Llc Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2877986A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
BR112016015797B1 (pt) 2014-01-13 2022-10-11 Amgen Inc Método para diminuir o teor de glicoforma de alta manose de uma proteína recombinante e método de produção de uma proteína recombinante
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
IL294430B2 (en) 2014-06-04 2025-08-01 Amgen Inc Methods for harvesting mammalian cell cultures
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
CA2982246A1 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
CA3036997A1 (en) 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
BR112019021977A2 (pt) 2017-04-20 2020-06-16 Egenesis, Inc. Métodos para a geração de animais geneticamente modificados
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
TWI865587B (zh) 2019-12-06 2024-12-11 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
KR20230008830A (ko) 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
CA3184812A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
KR20240125949A (ko) 2021-12-16 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 바이러스 불활성화를 위한 세제
JP2025507793A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
AU7317401A (en) * 2000-07-03 2002-01-14 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule

Also Published As

Publication number Publication date
CY1117625T1 (el) 2017-04-26
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
EP1536234B1 (en) 2016-03-16
NO330797B1 (no) 2011-07-18
CA2409748C (en) 2008-09-16
ATE271066T1 (de) 2004-07-15
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
AR031699A1 (es) 2003-10-01
NO20025656D0 (no) 2002-11-25
NO2011027I1 (no) 2012-01-09
NO20025656L (no) 2002-11-25
MY136113A (en) 2008-08-29
HUP0302201A3 (en) 2010-01-28
EE05557B1 (et) 2012-08-15
UY26723A1 (es) 2001-12-28
BRPI0111191B8 (pt) 2021-05-25
JP2004511213A (ja) 2004-04-15
IL152315A0 (en) 2003-05-29
DK1248802T3 (da) 2004-11-15
PE20011338A1 (es) 2002-01-13
CN1441810A (zh) 2003-09-10
CN1309735C (zh) 2007-04-11
TWI314933B (en) 2009-09-21
CA2409748A1 (en) 2001-12-06
JP4328525B2 (ja) 2009-09-09
CZ304451B6 (cs) 2014-05-14
TWI319405B (en) 2010-01-11
TR200402703T4 (tr) 2004-11-22
BE2011C041I2 (es) 2020-08-20
SI1248802T1 (en) 2005-02-28
DE60104282T2 (de) 2005-10-13
KR20030009502A (ko) 2003-01-29
DE122011100063I1 (de) 2012-06-14
EP1248802B9 (en) 2005-05-11
HK1071931A1 (en) 2005-08-05
AU2001263466B2 (en) 2006-04-27
AU2001263466C1 (en) 2006-10-26
UA87432C2 (uk) 2009-07-27
ZA200208944B (en) 2004-02-13
FR11C0053I1 (es) 2012-01-13
HK1048126A1 (en) 2003-03-21
LV12994B (en) 2003-08-20
CY2011019I2 (el) 2016-12-14
NO2011027I2 (es) 2011-12-15
PL206267B1 (pl) 2010-07-30
KR100895134B1 (ko) 2009-05-04
CN101255192A (zh) 2008-09-03
HUP0302201A2 (hu) 2003-10-28
IL152315A (en) 2010-04-15
SK15702002A3 (sk) 2004-01-08
PT1248802E (pt) 2004-11-30
CZ20023892A3 (cs) 2003-09-17
BR0111191A (pt) 2004-07-06
CY2011019I1 (el) 2016-12-14
EP1536234A3 (en) 2009-06-03
MXPA02011534A (es) 2004-08-12
DE60104282D1 (de) 2004-08-19
EG24459A (en) 2009-07-16
EP1536234A2 (en) 2005-06-01
GEP20053658B (en) 2005-11-10
BRPI0111191B1 (pt) 2019-12-31
EE201100050A (et) 2011-10-17
HUS1300012I1 (hu) 2016-08-29
WO2001092337A2 (en) 2001-12-06
EE200200659A (et) 2004-06-15
LT2002114A (en) 2003-12-29
PL366231A1 (en) 2005-01-24
HU228137B1 (en) 2012-12-28
LT5133B (lt) 2004-05-25
EP1248802A2 (en) 2002-10-16
EP1248802B1 (en) 2004-07-14
ES2225549T3 (es) 2005-03-16
FR11C0053I2 (fr) 2013-01-11
EP3029062A1 (en) 2016-06-08
TW200906857A (en) 2009-02-16
RU2283847C2 (ru) 2006-09-20
AU6346601A (en) 2001-12-11
EE05458B1 (et) 2011-08-15
HK1048126B (en) 2005-03-04
KR100889887B1 (ko) 2009-03-24
ES2571852T3 (es) 2016-05-27

Similar Documents

Publication Publication Date Title
ECSP024365A (es) Moleculas mutantes solubles ctla4 y sus aplicaciones
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
DE60236861D1 (de) Kombinatorische bibliotheken von monomerdomänen
ATE304583T1 (de) Klebstoffzusammensetzungen aus pflanzlichem protein
CY1105194T1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
CY1114584T1 (el) Ανασυνδυασμενα εμβολια και χρηση αυτων
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
CY1107759T1 (el) Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
NO20054790L (no) Anvendelse av B7-113 som et immunoregulatorisk middel
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
DE60116359D1 (de) Kahalalid f formulierung
PA8508301A1 (es) Inhibidores de la proteina c del procolageno
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
DE60324799D1 (de) Em material bestehende schuppen
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
CY1110718T1 (el) Ανοσογονες λιποσωμικες συνθεσεις